Journal
ANTIOXIDANTS & REDOX SIGNALING
Volume 31, Issue 13, Pages 954-993Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/ars.2019.7818
Keywords
HMGB1; inflammatory lung injury; pulmonary infection; pulmonary vascular remodeling; fibrosis; cancer
Funding
- National Heart and Blood Institute [HL093708]
- St. John's University
Ask authors/readers for more resources
Recent Advances: HMGB1 has been identified as a biomarker and mediator of the pathogenesis of numerous lung disorders. In addition, posttranslational modifications of HMGB1, including acetylation, phosphorylation, and oxidation, have been postulated to affect its localization and physiological and pathophysiological effects, such as the initiation and progression of lung diseases. Critical Issues: The molecular mechanisms underlying how HMGB1 drives the pathogenesis of different lung diseases and novel therapeutic approaches targeting HMGB1 remain to be elucidated. Future Directions: Additional research is needed to identify the roles and functions of modified HMGB1 produced by different posttranslational modifications and their significance in the pathogenesis of lung diseases. Such studies will provide information for novel approaches targeting HMGB1 as a treatment for lung diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available